DXRX - Ticker AI Digest

Diaceutics PLC 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Diaceutics PLC in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
DXRX Data 2026-01-15 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (DXRX) 1
DXRX 06:01
Diaceutics PLC
Full Year 2025 Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Diaceutics PLC Full Year 2025 Trading Update Summary**
Diaceutics PLC, a leading technology and solutions provider to the pharma and biotech industry, reported strong financial performance for FY 2025, highlighting significant growth and a return to profitability. Key highlights include
**Revenue Growth**Reported revenues of £38.5 million, up 20% year-on-year (YoY), with constant currency growth of 24%, in line with analyst consensus estimates.
**Profitability**Returned to profitability with Adjusted EBITDA exceeding analyst expectations, growing approximately 75% YoY to a margin of 19%.
**Record Order Book**Multi-year order book expanded to over £36.8 million, a 48% YoY increase, providing strong revenue visibility.
**ARR Growth**Annual Recurring Revenue (ARR) increased 21% to over £20.3 million, driven by deeper enterprise-wide customer engagements.
**Customer Expansion**Added three new enterprise-wide customers, including a second PMx commercialisation partnership with a leading US biotech. Now supports 18 of the top 20 global pharma companies and 95 therapeutic brands (up 12%).
**Strategic Progress**Accelerated adoption of AI across the business, enhancing scalability and operational efficiency.
**Outlook**Expects 25% revenue growth in FY 2026, supported by a strong pipeline and continued shift to precision medicine in the industry.
CEO Ryan Keeling emphasized the company’s successful execution of its value-creation strategy, focusing on scale, profitability, and recurring revenues, despite a challenging industry backdrop. Diaceutics remains well-positioned for continued growth and value creation in 2026.
Below is the HTML table code comparing the financials and debt (where applicable) year-on-year based on the provided text. Since debt information is not explicitly mentioned, the table focuses on key financial metrics:
MetricFY 2024FY 2025YoY Growth
Reported Revenues (£ million)32.238.520%
Constant Currency Revenue (£ million)N/A40.024%
Adjusted EBITDA (£ million)N/A>7.1*~75%
Annual Recurring Revenue (ARR) (£ million)16.8>20.321%
Order Book (£ million)24.9>36.848%
Number of Customer Therapeutic Brands859512%
Enterprise-Wide Engagements ARR (£ million)10.613.023%
Debt InformationNot provided in the text
* Adjusted EBITDA for FY 2025 is expected to exceed analyst consensus of £7.1 million.
### Notes: 1. **Debt Information**: The provided text does not include debt-related metrics, so the table reflects this as "Not provided." 2. **Adjusted EBITDA**: The FY 2025 figure is noted as exceeding £7.1 million (analyst consensus), so it is represented as ">7.1". 3. **YoY Growth**: Calculated based on available data. Where exact figures are not provided, approximate growth rates are used. 4. **Currency**: All figures are in £ million unless otherwise specified.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
DXRX 06:01
Diaceutics PLC
PDMR Shareholding/SIP & Total Voting Rights
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
DXRX 06:01
Diaceutics PLC
Full Year 2025 Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Diaceutics PLC Full Year 2025 Trading Update Summary**
Diaceutics PLC, a leading technology and solutions provider to the pharma and biotech industry, reported strong financial performance for FY 2025, highlighting significant growth and a return to profitability. Key highlights include
**Revenue Growth**Reported revenues of £38.5 million, up 20% year-on-year (YoY), with constant currency growth of 24%, in line with analyst consensus estimates.
**Profitability**Returned to profitability with Adjusted EBITDA exceeding analyst expectations, growing approximately 75% YoY to a margin of 19%.
**Record Order Book**Multi-year order book expanded to over £36.8 million, a 48% YoY increase, providing strong revenue visibility.
**ARR Growth**Annual Recurring Revenue (ARR) increased 21% to over £20.3 million, driven by deeper enterprise-wide customer engagements.
**Customer Expansion**Added three new enterprise-wide customers, including a second PMx commercialisation partnership with a leading US biotech. Now supports 18 of the top 20 global pharma companies and 95 therapeutic brands (up 12%).
**Strategic Progress**Accelerated adoption of AI across the business, enhancing scalability and operational efficiency.
**Outlook**Expects 25% revenue growth in FY 2026, supported by a strong pipeline and continued shift to precision medicine in the industry.
CEO Ryan Keeling emphasized the company’s successful execution of its value-creation strategy, focusing on scale, profitability, and recurring revenues, despite a challenging industry backdrop. Diaceutics remains well-positioned for continued growth and value creation in 2026.
Below is the HTML table code comparing the financials and debt (where applicable) year-on-year based on the provided text. Since debt information is not explicitly mentioned, the table focuses on key financial metrics:
MetricFY 2024FY 2025YoY Growth
Reported Revenues (£ million)32.238.520%
Constant Currency Revenue (£ million)N/A40.024%
Adjusted EBITDA (£ million)N/A>7.1*~75%
Annual Recurring Revenue (ARR) (£ million)16.8>20.321%
Order Book (£ million)24.9>36.848%
Number of Customer Therapeutic Brands859512%
Enterprise-Wide Engagements ARR (£ million)10.613.023%
Debt InformationNot provided in the text
* Adjusted EBITDA for FY 2025 is expected to exceed analyst consensus of £7.1 million.
### Notes: 1. **Debt Information**: The provided text does not include debt-related metrics, so the table reflects this as "Not provided." 2. **Adjusted EBITDA**: The FY 2025 figure is noted as exceeding £7.1 million (analyst consensus), so it is represented as ">7.1". 3. **YoY Growth**: Calculated based on available data. Where exact figures are not provided, approximate growth rates are used. 4. **Currency**: All figures are in £ million unless otherwise specified.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 2
DXRX 06:01
Diaceutics PLC
Full Year 2025 Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Diaceutics PLC Full Year 2025 Trading Update Summary**
Diaceutics PLC, a leading technology and solutions provider to the pharma and biotech industry, reported strong financial performance for FY 2025, highlighting significant growth and a return to profitability. Key highlights include
**Revenue Growth**Reported revenues of £38.5 million, up 20% year-on-year (YoY), with constant currency growth of 24%, in line with analyst consensus estimates.
**Profitability**Returned to profitability with Adjusted EBITDA exceeding analyst expectations, growing approximately 75% YoY to a margin of 19%.
**Record Order Book**Multi-year order book expanded to over £36.8 million, a 48% YoY increase, providing strong revenue visibility.
**ARR Growth**Annual Recurring Revenue (ARR) increased 21% to over £20.3 million, driven by deeper enterprise-wide customer engagements.
**Customer Expansion**Added three new enterprise-wide customers, including a second PMx commercialisation partnership with a leading US biotech. Now supports 18 of the top 20 global pharma companies and 95 therapeutic brands (up 12%).
**Strategic Progress**Accelerated adoption of AI across the business, enhancing scalability and operational efficiency.
**Outlook**Expects 25% revenue growth in FY 2026, supported by a strong pipeline and continued shift to precision medicine in the industry.
CEO Ryan Keeling emphasized the company’s successful execution of its value-creation strategy, focusing on scale, profitability, and recurring revenues, despite a challenging industry backdrop. Diaceutics remains well-positioned for continued growth and value creation in 2026.
Below is the HTML table code comparing the financials and debt (where applicable) year-on-year based on the provided text. Since debt information is not explicitly mentioned, the table focuses on key financial metrics:
MetricFY 2024FY 2025YoY Growth
Reported Revenues (£ million)32.238.520%
Constant Currency Revenue (£ million)N/A40.024%
Adjusted EBITDA (£ million)N/A>7.1*~75%
Annual Recurring Revenue (ARR) (£ million)16.8>20.321%
Order Book (£ million)24.9>36.848%
Number of Customer Therapeutic Brands859512%
Enterprise-Wide Engagements ARR (£ million)10.613.023%
Debt InformationNot provided in the text
* Adjusted EBITDA for FY 2025 is expected to exceed analyst consensus of £7.1 million.
### Notes: 1. **Debt Information**: The provided text does not include debt-related metrics, so the table reflects this as "Not provided." 2. **Adjusted EBITDA**: The FY 2025 figure is noted as exceeding £7.1 million (analyst consensus), so it is represented as ">7.1". 3. **YoY Growth**: Calculated based on available data. Where exact figures are not provided, approximate growth rates are used. 4. **Currency**: All figures are in £ million unless otherwise specified.
DXRX 06:01
Diaceutics PLC
PDMR Shareholding/SIP & Total Voting Rights
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for DXRX.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-01-15 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
Diaceutics PLC has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
DXRX signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Diaceutics PLC. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full DXRX Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for DXRX on 2026-01-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
121.0M
Enterprise Value
44.8M
Public Float
57.5
Broker Target
213
Shares Out
84.6M
Long Interest
100
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB00BJQTGV64
Market
LSE - AIM
Sector
Health Care Providers
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for DXRX.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-01-15 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Diaceutics PLC has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-05-11
Net Debt
-6.2M
Cash
7.3M
EPS
-
Net Income
97.0K
Revenue
38.4M
Enterprise Value
44.8M
Trailing PE
-
Forward PE
196.0784
Price Sales TTM
3.1485
Price Book MRQ
2.9896
EV Revenue
2.9874
EV EBITDA
18.6047
Financial Forecastist

Improving financial engine

Revenue is accelerating +73.3% against the prior comparable period. Net margin is expanding by 12.4 pts. Net debt is coming down +60.0%.

Revenue +73.3% Net Income -1057.1% FCF +23.9% Current Ratio 3.43x Forward Rev 0
Improving
Quarter Revenue
23.9M
+73.3%
vs prior comparable quarter
Net Margin
+10.5%
+12.4 pts
profitability pulse
Free Cash Flow
680.0K
+23.9%
cash conversion
Net Debt / EBITDA
-1.0x
-60.0%
lower is cleaner
Revenue Engine

Latest quarter printed 23.9M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 2.5M and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 7.3M while net debt is -6.2M. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
46.5M
Revenue Path
0.01
EPS / Earnings
Growth cue -0.1%
FY 2027
Consensus
56.9M
Revenue Path
0.04
EPS / Earnings
Growth cue +5.4%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 23.9M 2.5M 680.0K -6.2M
Q2 2025 14.6M -2.4M 550.0K -9.2M
Q4 2024 19.8M 881.0K -540.0K -11.7M
Q2 2024 12.3M -2.6M 1.4M -16.6M
Q4 2023 13.8M -261.0K 549.0K -15.5M
Q2 2023 9.9M -1.5M -2.0M -16.6M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 38.4M 97.0K 5.6M 1.4M
FY 2024 32.2M -1.7M 2.8M -4.0M
FY 2023 23.7M -1.7M 2.4M -3.5M
FY 2022 19.5M 724.0K 3.6M 278.0K
FY 2021 13.9M 561.0K 2.3M -5.0M

Structure DNA

Market Structure DNA

Institutional Trend Leader profile with trend runway open

Price is 81.6% through the 52-week range, +7.0% vs 50DMA and +10.1% vs 200DMA. 91.2% of the register is locked by institutions and insiders, leaving 8.8% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend runway open Institutional gravity Moderate income rhythm As Of 2026-04-19
Institutional Trend Leader
Structure Score
66.1 / 100
Institutional Trend Leader
Trend Stack
+7.0% / +10.1%
vs 50DMA / 200DMA
52W Position
81.6%
auction position inside the yearly range
Ownership Lock
91.2%
62.8% institutions | 28.5% insiders
Pressure Pocket
8.8% free float
Vendor short-float fields were not supplied
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 164.50 with the stock +7.0% vs 50DMA and +10.1% vs 200DMA. The tape is sitting 81.6% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 62.8% and insiders about 28.5%, locking roughly 91.2% of the register and leaving 8.8% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
164.50
derived from market cap / shares
52W High
176.25
upper auction edge
52W Low
112.25
lower auction edge
Beta
0.94
volatility character
Shares Out
84.6M
fully diluted count
Shares Float
48.4M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
23.1282
Institutions As Of
2026-05-12
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
3
Broker Coverage Rows
1
Institution Holders Tracked
3
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for DXRX, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-01-15 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Diaceutics PLC has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
DXRX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-01-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast -4.84%
RSI Gauge
Price Change
AI Forecast